1 Table of Contents

1 Table of Contents 5

• 1.1 List of Tables 7
• 1.2 List of Figures 8

2 Introduction 12

• 2.1 Therapy Area Overview 12
  • 2.1.1 Rheumatoid Arthritis 12
  • 2.1.2 Osteoarthritis 13
  • 2.1.3 Osteoporosis 14
  • 2.1.4 Systemic Lupus Erythematosus 15
  • 2.1.5 Psoriatic Arthritis 16
• 2.2 Etiology 17
• 2.3 Pathophysiology 19
  • 2.3.1 Rheumatoid Arthritis 19
  • 2.3.2 Osteoarthritis 20
  • 2.3.3 Osteoporosis 20
  • 2.3.4 Systemic Lupus Erythematosus 21
  • 2.3.5 Psoriatic Arthritis 22
• 2.4 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 23
  • 2.4.1 Rheumatoid Arthritis 24
  • 2.4.2 Osteoarthritis 25
  • 2.4.3 Osteoporosis 26
  • 2.4.4 Systemic Lupus Erythematosus 27
  • 2.4.5 Psoriatic arthritis 28
• 2.5 Treatment 29
  • 2.5.1 Rheumatoid Arthritis 29
  • 2.5.2 Osteoarthritis 31
  • 2.5.3 Osteoporosis 32
  • 2.5.4 Systemic Lupus Erythematosus 35
  • 2.5.5 Psoriatic Arthritis 37

3 Key Marketed Products 40

• 3.1 Overview 40
• 3.2 Humira (adalimumab) - AbbVie 41
• 3.3 Enbrel (etanercept) - Amgen 44
• 3.4 Simponi (golimumab) - Johnson & Johnson 46
• 3.5 Remicade (infliximab) - Johnson & Johnson 48
• 3.6 Rituxan (rituximab) - Roche 51
• 3.7 Stelara (ustekinumab) - Johnson & Johnson 52
• 3.8 Cosentyx (secukinumab) - Novartis 54
• 3.9 Prolia (denosumab) - Amgen 55
• 3.10 Orencia (abatacept) - Bristol-Myers Squibb 57
• 3.11 Actemra (tocilizumab) - Roche 59
• 3.12 Benlysta (belimumab) - GlaxoSmithKline 60
• 3.13 Forteo (teriparatide) - Eli Lilly 62

4 Pipeline Landscape Assessment 64

• 4.1 Overview 64
• 4.2 Pipeline Development Landscape 64
• 4.3 Molecule Types in the Pipeline 67
• 4.4 Molecular Targets in the Pipeline 68
• 4.5 Clinical Trials Landscape 70
  • 4.5.1 Clinical Trial Failure Rates 70
  • 4.5.2 Clinical Trial Duration 73
  • 4.5.3 Clinical Trial Size 77
  • 4.5.4 Cumulative Clinical Program Size 81
• 4.6 Assessment of Key Pipeline Products 85
  • 4.6.1 Upadacitinib tartrate - AbbVie 85
  • 4.6.2 Filgotinib - Gilead Sciences 86
  • 4.6.3 Lenabasum - Corbus Pharmaceuticals 88
  • 4.6.4 Evenity (romosozumab) - Amgen / UCB / Astellas 89
  • 4.6.5 Avacopan - ChemoCentryx 90
  • 4.6.6 Pegadricase - Selecta Biosciences 92
  • 4.6.7 Anifrolumab - AstraZeneca 94

5 Multi-scenario Market Forecast to 2024 96

• 5.1 Overall Market Size 96
• 5.2 Generic Penetration 99
• 5.3 Revenue Forecast by Molecular Target 101
  • 5.3.1 Products Acting on Tumor Necrosis Factor-Alpha 101
  • 5.3.2 Products Acting on Interleukins and Interleukin Receptors 102
  • 5.3.3 Products Acting on Protein Kinases 103
  • 5.3.4 Products Acting on Cell Surface Antigens 104
  • 5.3.5 Products Acting on Hormones and Hormone Receptors 105

6 Company Analysis and Positioning 107

• 6.1 Revenue and Market Share Analysis by Company 109
  • 6.1.1 AbbVie 117
  • 6.1.2 Amgen 118
  • 6.1.3 Johnson & Johnson 119
  • 6.1.4 Novartis 120
  • 6.1.5 Pfizer 122
  • 6.1.6 Roche 124
  • 6.1.7 Eli Lilly 125
  • 6.1.8 Bristol-Myers Squibb 126
• 6.2 Company Landscape 127
• 6.3 Marketed and Pipeline Portfolio Analysis 129

7 Strategic Consolidations 131

• 7.1 Licensing Deals 131
  • 7.1.1 Deals by Region, Year and Value 131
  • 7.1.2 Deals by Indication and Value 133
  • 7.1.3 Deals by Stage of Development and Value 134
  • 7.1.4 Deals by Molecule Type, Molecular Target and Value 135
  • 7.1.5 Licensing Deals with Disclosed Values 136
• 7.2 Co-development Deals 142
  • 7.2.1 Deals by Region, Year and Value 142
  • 7.2.2 Deals by Indication and Value 143
  • 7.2.3 Deals by Stage of Development and Value 144
  • 7.2.4 Deals by Molecule Type, Molecular Target and Value 145
  • 7.2.5 Co-development Deals with Disclosed Values 146

8 Appendix 149

• 8.1 References 149
• 8.2 Figures of All Clinical Stage Pipeline Products 162
• 8.3 Abbreviations 176
• 8.4 Disease List 177
• 8.5 Methodology 177
  • 8.5.1 Coverage 178
  • 8.5.2 Secondary Research 178
  • 8.5.3 Market Size and Revenue Forecasts 178
  • 8.5.4 Pipeline Analysis 179
  • 8.5.5 Competitive Landscape 179
• 8.6 Contact Us 179

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Summary

The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals